Follow‐Up of 3‐Year Luspatercept Treatment in a Transfused ß‐Thalassemia Patient. Bone Marrow: An Undervalued Iron Store
Luspatercept treatment affects the informative value of ferritin and LIC in the assessment of total body iron stores, which should be considered in the management of iron chelation therapy.
Authors
- Isabel Molwitz (ORCID: https://orcid.org/0000-0003-4542-0140)
- Roland A. Fischer (ORCID: https://orcid.org/0000-0002-7532-5286)
- Surjit K. Datta
- Regine Grosse
- Matthias Bleeke (ORCID: https://orcid.org/0000-0003-0455-8338)
- Filomena Longo (ORCID: https://orcid.org/0000-0002-0434-0382)
- C. Niekrens
Institutions
- Universität Hamburg (DE)
- University of Ferrara (IT)
- University Medical Center Hamburg-Eppendorf (DE)
- Gemeinschaftsklinikum Mittelrhein (DE)
- Institute for Advanced Study (DE)
Publication Details
- Journal
- eJHaem
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1002/jha2.70193
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00